Related Experiment Video
Updated: May 5, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
[New perspectives in the management of small cell bronchial cancer]
Elodie Berton1, Camille Ardin1, Giulia Berardi1
1UM oncologie thoracique SHUPP, PTV CHU Grenoble Alpes, Grenoble, France.
Abstract:
Small cell lung cancer (SCLC) remains one of the most aggressive cancers, with an overall survival of approximately one year for patients with extensive stage SCLC, and we still have very few effective therapies, especially after the first line of treatment. A better understanding of SCLC and their mechanisms, especially molecular mechanisms, has led to the exploration of new therapeutic strategies. For example, transcriptomic analyses have identified 4 subtypes of CBPC, which could be predictive of response to treatments. Immune checkpoint inhibitors have shown limited benefit in extensive stage SCLC, but appear to have a clear benefit for limited stage SCLC, in association with radio-chemotherapy. Anti- PARP molecules, involved in DNA repair and aberrantly expressed in CBPC, have been studied. New molecules have been developed, to bypass antigen presentation, which is defective in SCLC; such as bispecific T-cell engager molecules, that binds to SCLC cells and patient's cytotoxic T-cell, leading to T-cell activation and tumor lysis. These molecules target tumor cell's surface proteins, such as delta-like ligand 3 (DLL3), aberrantly expressed on the surface of most SCLC cells. Tarlamab, a DLL3-targeted immune therapy, has shown very promising durable responses in patients with previously treated SCLC. These new molecules lead to new side effects we will have to manage, such as the Cytokine Relargage Syndrome. Other molecules, targeting DLL3 or other pathways are still ungoing clinical evaluation, we should see further advances in the treatment of SCLC over the coming years.
Insights
Small cell lung cancer (SCLC) treatments are limited. New therapies, including bispecific T-cell engagers targeting DLL3, show promise for aggressive SCLC, offering hope for improved patient survival.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Small cell lung cancer (SCLC) is highly aggressive with poor survival rates, especially in extensive stages.
- Current therapies for SCLC are limited, particularly for patients progressing after first-line treatment.
- Understanding SCLC molecular mechanisms is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To explore emerging therapeutic strategies for small cell lung cancer (SCLC).
- To review novel molecular mechanisms and targeted therapies for SCLC treatment.
- To discuss the potential of new agents like bispecific T-cell engagers in SCLC management.
Main Methods:
- Review of transcriptomic analyses identifying SCLC subtypes.
- Evaluation of immune checkpoint inhibitors' efficacy in different SCLC stages.
- Analysis of novel therapeutic molecules, including anti-PARP agents and bispecific T-cell engagers targeting DLL3.
- Assessment of clinical data for Tarlatamb, a DLL3-targeted therapy.
Main Results:
- Transcriptomic analysis revealed 4 SCLC subtypes potentially predicting treatment response.
- Immune checkpoint inhibitors show benefit in limited-stage SCLC with radio-chemotherapy.
- Bispecific T-cell engagers, like Tarlatamb targeting DLL3, demonstrate promising durable responses in pre-treated SCLC patients.
- New therapies introduce manageable side effects such as Cytokine Relargage Syndrome.
Conclusions:
- Novel therapeutic strategies targeting molecular pathways and immune responses are advancing SCLC treatment.
- DLL3-targeted therapies, such as Tarlatamb, represent a significant development for previously treated SCLC.
- Further clinical evaluations of DLL3-targeting agents and other pathways are expected to improve SCLC outcomes.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:24Cystic Fibrosis: Management
Sinus disease and chronic...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation